Guadalajara, Mexico

Renati Innovation S.A.P.I. de C.V.

Non-Small-Cell Lung Carcinoma

Summit Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Renati Innovation S.A.P.I. de C.V. | Guadalajara, Mexico

Site insights

Work at this site?

Active trials

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Trial sponsors